Literature DB >> 26062848

Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia.

Yiting Lim1, Lukasz Gondek1, Li Li1, Qiuju Wang1, Hayley Ma1, Haley Ma, Emily Chang1, David L Huso1, Sarah Foerster1, Luigi Marchionni1, Karen McGovern2, David Neil Watkins3, Craig D Peacock4, Mark Levis1, Bruce Douglas Smith1, Akil A Merchant5, Donald Small6, William Matsui7.   

Abstract

FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) mutations resulting in constitutive kinase activity are common in acute myeloid leukemia (AML) and carry a poor prognosis. Several agents targeting FLT3 have been developed, but their limited clinical activity suggests that the inhibition of other factors contributing to the malignant phenotype is required. We examined gene expression data sets as well as primary specimens and found that the expression of GLI2, a major effector of the Hedgehog (Hh) signaling pathway, was increased in FLT3-ITD compared to wild-type FLT3 AML. To examine the functional role of the Hh pathway, we studied mice in which Flt3-ITD expression results in an indolent myeloproliferative state and found that constitutive Hh signaling accelerated the development of AML by enhancing signal transducer and activator of transcription 5 (STAT5) signaling and the proliferation of bone marrow myeloid progenitors. Furthermore, combined FLT3 and Hh pathway inhibition limited leukemic growth in vitro and in vivo, and this approach may serve as a therapeutic strategy for FLT3-ITD AML.
Copyright © 2015, American Association for the Advancement of Science.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26062848      PMCID: PMC4644635          DOI: 10.1126/scitranslmed.aaa5731

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  73 in total

1.  Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23).

Authors:  Y Matsuo; R A MacLeod; C C Uphoff; H G Drexler; C Nishizaki; Y Katayama; G Kimura; N Fujii; E Omoto; M Harada; K Orita
Journal:  Leukemia       Date:  1997-09       Impact factor: 11.528

2.  Stat5 tetramer formation is associated with leukemogenesis.

Authors:  Richard Moriggl; Veronika Sexl; Lukas Kenner; Christopher Duntsch; Katharina Stangl; Sebastien Gingras; Angelika Hoffmeyer; Anton Bauer; Roland Piekorz; Demin Wang; Kevin D Bunting; Erwin F Wagner; Karoline Sonneck; Peter Valent; James N Ihle; Hartmut Beug
Journal:  Cancer Cell       Date:  2005-01       Impact factor: 31.743

3.  Inducible gene targeting in mice.

Authors:  R Kühn; F Schwenk; M Aguet; K Rajewsky
Journal:  Science       Date:  1995-09-08       Impact factor: 47.728

4.  Prognostically useful gene-expression profiles in acute myeloid leukemia.

Authors:  Peter J M Valk; Roel G W Verhaak; M Antoinette Beijen; Claudia A J Erpelinck; Sahar Barjesteh van Waalwijk van Doorn-Khosrovani; Judith M Boer; H Berna Beverloo; Michael J Moorhouse; Peter J van der Spek; Bob Löwenberg; Ruud Delwel
Journal:  N Engl J Med       Date:  2004-04-15       Impact factor: 91.245

5.  Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.

Authors:  B Douglas Smith; Mark Levis; Miloslav Beran; Francis Giles; Hagop Kantarjian; Karin Berg; Kathleen M Murphy; Tianna Dauses; Jeffrey Allebach; Donald Small
Journal:  Blood       Date:  2004-01-15       Impact factor: 22.113

6.  Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.

Authors:  Richard M Stone; Daniel J DeAngelo; Virginia Klimek; Ilene Galinsky; Eli Estey; Stephen D Nimer; Wilson Grandin; David Lebwohl; Yanfeng Wang; Pamela Cohen; Edward A Fox; Donna Neuberg; Jennifer Clark; D Gary Gilliland; James D Griffin
Journal:  Blood       Date:  2004-09-02       Impact factor: 22.113

7.  Cooperation between sonic hedgehog and fibroblast growth factor/MAPK signalling pathways in neocortical precursors.

Authors:  Nicoletta Kessaris; Françoise Jamen; Lee L Rubin; William D Richardson
Journal:  Development       Date:  2004-02-11       Impact factor: 6.868

8.  Dysregulated Sonic hedgehog signaling and medulloblastoma consequent to IFN-alpha-stimulated STAT2-independent production of IFN-gamma in the brain.

Authors:  Jianping Wang; Ngan Pham-Mitchell; Christian Schindler; Iain L Campbell
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

9.  Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.

Authors:  Stefan Fröhling; Richard F Schlenk; Jochen Breitruck; Axel Benner; Sylvia Kreitmeier; Karen Tobis; Hartmut Döhner; Konstanze Döhner
Journal:  Blood       Date:  2002-08-08       Impact factor: 22.113

10.  Diminished Sonic hedgehog signaling and lack of floor plate differentiation in Gli2 mutant mice.

Authors:  Q Ding; J Motoyama; S Gasca; R Mo; H Sasaki; J Rossant; C C Hui
Journal:  Development       Date:  1998-07       Impact factor: 6.868

View more
  26 in total

1.  Rational for targeting the hedgehog signalling pathway in acute myeloid leukemia with FLT3 mutation.

Authors:  Didier Bouscary
Journal:  Ann Transl Med       Date:  2016-10

2.  GLI3 repressor determines Hedgehog pathway activation and is required for response to SMO antagonist glasdegib in AML.

Authors:  Parvesh Chaudhry; Mohan Singh; Timothy J Triche; Monica Guzman; Akil A Merchant
Journal:  Blood       Date:  2017-05-09       Impact factor: 22.113

3.  A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS).

Authors:  David A Sallman; Rami S Komrokji; Kendra L Sweet; Qianxing Mo; Kathy L McGraw; Vu H Duong; Ling Zhang; Lisa Ann Nardelli; Eric Padron; Alan F List; Jeffrey E Lancet
Journal:  Leuk Res       Date:  2019-03-30       Impact factor: 3.156

4.  Hedgehog/GLI1 activation leads to leukemic transformation of myelodysplastic syndrome in vivo and GLI1 inhibition results in antitumor activity.

Authors:  Bonnie W Lau; Kyounghee Huh; Rafael Madero-Marroquin; Federico De Marchi; Yiting Lim; Qiuju Wang; Francisco Lobo; Luigi Marchionni; Douglas B Smith; Amy DeZern; Mark J Levis; Peter D Aplan; William Matsui; Lukasz P Gondek
Journal:  Oncogene       Date:  2018-08-31       Impact factor: 9.867

Review 5.  Regulation of normal and leukemic stem cells through cytokine signaling and the microenvironment.

Authors:  Virginia Camacho; Victoria McClearn; Sweta Patel; Robert S Welner
Journal:  Int J Hematol       Date:  2017-02-07       Impact factor: 2.490

Review 6.  Hedgehog Pathway Inhibitors: A New Therapeutic Class for the Treatment of Acute Myeloid Leukemia.

Authors:  Catriona Jamieson; Giovanni Martinelli; Cristina Papayannidis; Jorge E Cortes
Journal:  Blood Cancer Discov       Date:  2020-08-11

Review 7.  Update on rational targeted therapy in AML.

Authors:  Danielle Shafer; Steven Grant
Journal:  Blood Rev       Date:  2016-02-22       Impact factor: 8.250

Review 8.  FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions.

Authors:  Maria Larrosa-Garcia; Maria R Baer
Journal:  Mol Cancer Ther       Date:  2017-06       Impact factor: 6.261

Review 9.  Hedgehog Signaling in the Maintenance of Cancer Stem Cells.

Authors:  Catherine R Cochrane; Anette Szczepny; D Neil Watkins; Jason E Cain
Journal:  Cancers (Basel)       Date:  2015-08-11       Impact factor: 6.639

Review 10.  The contribution of single-cell analysis of acute leukemia in the therapeutic strategy.

Authors:  Lamia Madaci; Julien Colle; Geoffroy Venton; Laure Farnault; Béatrice Loriod; Régis Costello
Journal:  Biomark Res       Date:  2021-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.